KR100544295B1 - 에이엠피에이 수용체 활성을 증가시키는 벤조퓨란 화합물 - Google Patents

에이엠피에이 수용체 활성을 증가시키는 벤조퓨란 화합물 Download PDF

Info

Publication number
KR100544295B1
KR100544295B1 KR1019997007369A KR19997007369A KR100544295B1 KR 100544295 B1 KR100544295 B1 KR 100544295B1 KR 1019997007369 A KR1019997007369 A KR 1019997007369A KR 19997007369 A KR19997007369 A KR 19997007369A KR 100544295 B1 KR100544295 B1 KR 100544295B1
Authority
KR
South Korea
Prior art keywords
compound
ylcarbonyl
benzofuran
crr
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997007369A
Other languages
English (en)
Korean (ko)
Other versions
KR20000071082A (ko
Inventor
개리 에이. 로저스
크리스토퍼 엠. 마스
Original Assignee
리전츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리전츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 리전츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20000071082A publication Critical patent/KR20000071082A/ko
Application granted granted Critical
Publication of KR100544295B1 publication Critical patent/KR100544295B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
  • Furan Compounds (AREA)
KR1019997007369A 1997-02-13 1998-02-13 에이엠피에이 수용체 활성을 증가시키는 벤조퓨란 화합물 Expired - Fee Related KR100544295B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8/800,108 1997-02-13
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses
US08/800,108 1997-02-13
PCT/US1998/002713 WO1998035950A1 (en) 1997-02-13 1998-02-13 Benzofurazan compounds which enhance ampa receptor activity

Publications (2)

Publication Number Publication Date
KR20000071082A KR20000071082A (ko) 2000-11-25
KR100544295B1 true KR100544295B1 (ko) 2006-01-23

Family

ID=25177504

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997007369A Expired - Fee Related KR100544295B1 (ko) 1997-02-13 1998-02-13 에이엠피에이 수용체 활성을 증가시키는 벤조퓨란 화합물

Country Status (24)

Country Link
US (3) US6110935A (https=)
EP (2) EP1428534B1 (https=)
JP (1) JP4446023B2 (https=)
KR (1) KR100544295B1 (https=)
CN (1) CN1085206C (https=)
AT (2) ATE266649T1 (https=)
AU (1) AU737802C (https=)
BR (1) BR9807333B1 (https=)
CA (1) CA2279319C (https=)
CZ (1) CZ299765B6 (https=)
DE (2) DE69834590T2 (https=)
DK (2) DK0960105T3 (https=)
ES (2) ES2264078T3 (https=)
GB (1) GB2325225B (https=)
HU (1) HUP0002303A3 (https=)
ID (1) ID22342A (https=)
IL (1) IL131200A (https=)
NO (1) NO318935B1 (https=)
NZ (1) NZ336980A (https=)
PL (1) PL199135B1 (https=)
PT (2) PT960105E (https=)
RU (1) RU2189984C2 (https=)
TR (1) TR199901941T2 (https=)
WO (1) WO1998035950A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (https=) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
EP1592464A4 (en) * 2003-01-13 2011-03-09 Cortex Pharma Inc METHOD OF TREATING COGNITIVE DECLINE FROM LACK OF SLEEP AND STRESS
DK1636215T3 (da) * 2003-05-23 2008-06-02 Basilea Pharmaceutica Ag Furazanobenzimidazoler
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
JP2010501597A (ja) 2006-08-31 2010-01-21 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ 正のアロステリックａｍｐａ受容体モジュレーターを用いて呼吸抑制を阻害する方法
CN101626686A (zh) * 2007-01-03 2010-01-13 科泰克斯药品公司 用于提高谷氨酸性突触反应的3-取代基-1,2,3-苯并三嗪酮类化合物
AP2502A (en) * 2007-01-03 2012-10-23 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8263591B2 (en) * 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
BRPI1005316A2 (pt) * 2009-02-02 2019-09-24 Cortex Pharmaceuticals, Inc. composto, composição farmacêuttca, métodos para tratamento e uso de um composto
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
EP2801377B1 (en) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1Ｈ-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
US20150011554A1 (en) 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
EP3436021A4 (en) 2016-03-29 2019-11-06 RespireRx Pharmaceuticals Inc. COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDER
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
SU1657189A1 (ru) * 1988-05-23 1991-06-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ коррекции апато-абулических состо ний при шизофрении
SU1587050A1 (ru) * 1988-12-23 1990-08-23 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Производные (7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амина в качестве промежуточных продуктов в синтезе 2-[(7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амино]-5-бром-N-(4-хлорфенил)бензамида, обладающего антигельминтной активностью
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
EP1367056A1 (en) * 1992-07-24 2003-12-03 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by AMPA receptors
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
IL131200A0 (en) 2001-01-28
AU6159998A (en) 1998-09-08
ES2221152T3 (es) 2004-12-16
EP0960105A1 (en) 1999-12-01
CZ299765B6 (cs) 2008-11-19
CN1085206C (zh) 2002-05-22
GB2325225A8 (en) 1999-02-17
GB9809221D0 (https=) 1998-07-01
RU2189984C2 (ru) 2002-09-27
GB2325225A (en) 1998-11-18
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
EP0960105B1 (en) 2004-05-12
KR20000071082A (ko) 2000-11-25
BR9807333A (pt) 2000-04-18
NO993768D0 (no) 1999-08-04
BR9807333B1 (pt) 2011-10-18
ID22342A (id) 1999-09-30
CA2279319C (en) 2008-08-05
DE69823803D1 (de) 2004-06-17
PT960105E (pt) 2004-09-30
PL199135B1 (pl) 2008-08-29
US6110935A (en) 2000-08-29
ATE266649T1 (de) 2004-05-15
AU737802B2 (en) 2001-08-30
US6313115B1 (en) 2001-11-06
PL335058A1 (en) 2000-03-27
PT1428534E (pt) 2006-07-31
ATE326221T1 (de) 2006-06-15
DE69823803T2 (de) 2005-04-14
US20020055508A1 (en) 2002-05-09
GB2325225B (en) 1999-03-03
ES2264078T3 (es) 2006-12-16
CZ279599A3 (cs) 2000-01-12
JP4446023B2 (ja) 2010-04-07
DK0960105T3 (da) 2004-08-30
DK1428534T3 (da) 2006-06-12
IL131200A (en) 2005-06-19
DE69834590D1 (de) 2006-06-22
CA2279319A1 (en) 1998-08-20
TR199901941T2 (xx) 1999-12-21
DE69834590T2 (de) 2007-04-26
HUP0002303A2 (hu) 2001-04-28
EP1428534B1 (en) 2006-05-17
EP1428534A1 (en) 2004-06-16
JP2001512459A (ja) 2001-08-21
WO1998035950A1 (en) 1998-08-20
AU737802C (en) 2005-05-12
CN1247534A (zh) 2000-03-15
NO318935B1 (no) 2005-05-30
HUP0002303A3 (en) 2002-09-30
US6730677B2 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
KR100544295B1 (ko) 에이엠피에이 수용체 활성을 증가시키는 벤조퓨란 화합물
DE69633245T2 (de) Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
EP2154970B1 (en) Di-substituted amides for enhancing glutamatergic synaptic responses
KR101769999B1 (ko) Ｎｍｄａ 수용체 조절제 및 그의 용도
JP2010540436A (ja) グルタミン酸作動性シナプス反応を増大するための３−置換１，２，３−トリアジン−４−オン及び３−置換１，３−ピリミジン−オン
RU2246498C2 (ru) Ацилбензоксазины для усиления синаптического ответа (ов)
JP4620349B2 (ja) グルタメートシナプシス応答向上のためのカルボニルベンゾキサジン化合物
US8507482B2 (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
EP0716657A1 (de) ALKOXY-SUBSTITUIERTE $g(b)-CARBOLINE MIT EINWIRKUNG AUF DEN AMPA-REZEPTOR
US20020055498A1 (en) Benzofurazan compounds for enhancing glutamatergic synaptic responses
MXPA99007361A (en) Benzofurazan compounds which enhance ampa receptor activity
JP2012516845A (ja) グルタミン酸作動性シナプス反応を増強するための二環式アミド誘導体
HK1142596A (en) 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20101222

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120112

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120112

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000